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1. Introduction 
Estimated, 225,000 new cases of ovarian cancer in the world in 2011, with approximately 
140,000 deaths. In the United States of America, ovarian cancer is the second most 
gynecological cancer. It is the most common cause of gynecological cancer related death 
primarily because most patients present with advanced disease. 65-70% of patients are 
diagnosed at an advanced stage, conferring a 5-year survival rate of 30-55%. Epithelial 
ovarian cancer (EOC) remains the most lethal gynecologic cancer in the United States. In 
2010, approximately 21,880 new cases and 13,850 deaths occurred. There is no proven 
screening test for this disease. Many women present with vague symptoms, including 
abdominal bloating, change in bowel or bladder habits, early satiety, or abdominal pain. It is 
diagnosed at advanced stage for about 75% of patients [1]. It spreads along the peritoneal 
surfaces to the upper abdomen by direct extension or by peritoneal implantation [2]. 
Metastases to the diaphragm, especially to the right hemi-diaphragm, are common in 
patients with advanced ovarian cancer. About 40% of patients with advanced ovarian cancer 
present with bulky metastatic diaphragmatic disease. About 19% of patients are diagnosed 
with International Federation of Obstetrics and Gynecology (FIGO) [Table 1.] stage I disease, 
in which the tumor is confined to one or both ovaries. (1). Stage I disease is usually 
diagnosed incidentally during laparoscopic or laparotomy surgery for benign-looking 
ovarian tumors, but, following complete staging, it is upstaged in 30% of patients due to 
microscopic metastatic disease.(2,3 ). FIGO guidelines have stated that the standard 
management for apparent early-stage disease is complete surgical staging, including total 
abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymph 
node dissection, infracolic omentectomy, multiple peritoneal washing, and multiple 
peritoneal biopsies (4). Initial evaluation includes a thorough history and physical 
examination, imaging studies such as MRI and computerized tomography scanning, 
assessment of tumor markers such as CA-125, biopsies, cystoscopy and colonoscopy. The 
standard treatment for primary ovarian cancer consists of maximum cytoreductive effort to 
reduce residual tumor (RT), followed by platinum-based chemotherapy (3, 4). It has been 
shown that cytoreduction has a more significant influence on survival than the extent of a 
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metastatic disease observed before surgery (5). This target has value in the primary 
cytoreduction (3), and in interval debulking surgery after neoadjuvant chemotherapy (6), in 
addition to in secondary cytoreduction in platinum-sensitive recurrent ovarian cancer 
patients (7). Extensive upper abdominal debulking surgery increases the rate of optimal 
cytoreduction and it is related with improved survival rates in advanced ovarian cancer 
undergoing primary cytoreduction and interval debulking surgery (8). Hepatic resection (9), 
splenectomy (10) and (11), video-assisted thoracic surgery (12), and diaphragmatic resection 
(13), (14), (15), (16), (17), (18) and (19) have been considered as components of primary 
cytoreduction when necessary.  
 
Stage I: Growth limited to the ovaries 
IA Growth limited to one ovary: no ascites present containing malignant cells. No tumor 
on the external surface; capsule intact. 
IB Growth limited to both ovaries: no ascites present containing malignant cells. No 
tumor on the external surfaces; capsules intact. 
IC* Tumor either stage IA or IB, but with tumor on surface of one or both ovaries, or with 
capsule ruptured, or with ascites present 
containing malignant cells, or with positive peritoneal washings. 
Stage II: Growth involving one or both ovaries with pelvic extension. 
IIA Extension and/or metastases to the uterus and/or tubes. 
IIB Extension to other pelvic tissues. 
IIC* Tumor either stage IIA or IIB, but with tumor on surface of one or both ovaries, or 
with capsule(s) ruptured, or with ascites present 
containing malignant cells, or with positive peritoneal washings. 
Stage III: Tumor involving one or both ovaries with histologically confirmed peritoneal 
implants outside the pelvis and/or positive retroperitoneal 
or inguinal nodes. Superficial liver metastases equals stage III. Tumor is limited to the 
true pelvis but with histologically proven 
malignant extension to small bowel or omentum. 
IIIA Tumor grossly limited to the true pelvis, with negative nodes, but with histologically 
confirmed microscopic seeding of abdominal 
peritoneal surfaces, or histologic proven extension to small bowel or mesentery. 
IIIB Tumor of one or both ovaries with histologically confirmed implants, peritoneal 
metastasis of abdominal peritoneal surfaces, none 
exceeding 2 cm in diameter; nodes are negative. 
IIIC Peritoneal metastasis beyond the pelvis > 2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes. 
Stage IV: Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allot a 
case to stage IV. Parenchymal liver metastasis equals stage IV. 
* In order to evaluate the impact on prognosis of the different criteria for allotting cases to 
stage IC or IIC, it would be of value to know if rupture of the 
capsule was spontaneous, or caused by the surgeon; and if the source of malignant cells 
detected peritoneal washings, or ascites. 
 
Table 1. Carcinoma of the ovary:  figo classification ( rio de janerio 1988) 
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2. Minimally invasive surgery in advanced ovarian cancer 
Laparoscopic assisted surgery can be utilized in the surgical management of apparent early-
stage ovarian cancer, in assessing resectability of advanced disease prior to laparotomy, and 
also in second-look procedures. 
Several studies showed that laparoscopy is safe and feasible in the surgical management of 
apparent early-stage ovarian cancer. (20-23) In a Study comparing laparoscopic treatment of 
gynecologic malignancies with traditional laparotomy for early-stage ovarian cancer, it was 
observed (24) that the acceptable survival rates with decreased morbidity and shorter 
hospitalization: 91.6% with disease-free survival and overall survival of 100% at 46 months. 
The advantages of laparoscopy are faster recovery with early return of bowel function and a 
shorter hospital stay. Laparoscopy can be useful, when deciding whether to proceed with 
primary cytoreductive surgery or neoadjuvant chemotherapy in advanced epithelial ovarian 
cancer. In a study of 87 patients who underwent diagnostic laparoscopy, 53 were considered 
resectable.(25). Of these 53 patients, 96% were optimally cytoreduced. Laparoscopy seems to 
be an acceptable method for assessing disease resectability. Operative time of 120 to 240 
minutes has been reported with laparoscopic staging of ovarian cancer (26). Surgical 
complications could include vascular and gastrointestinal injuries, and possibly port site 
metastases (27). There is a concerqn that ovarian cancer mass my rupture while trying to 
remove it. Ovarian cyst rupture has been reported in 12% to 25% of patients undergoing 
laparoscopy(,28,29) and rupture may cause intra-abdominal dissemination. Several studies 
have suggested that cyst rupture increase recurrence rate and decrease survival (30,31). To 
avoid any spillage, the ovarian mass should be placed in a laparoscopic bag and retrieved 
through the umbilical port or through a colpotomy. Minimally invasive robot- assisted 
laparoscopic surgery, utilizing da Vinci surgical system ( Figures 1 and 2), has been 
employed to duplicate traditional open procedures via small incisions in the skin with 
surgical outcomes equivalent or superior to a traditional surgical approach. Robotic surgery 
enables the operator to control the robotic system alone and to perform more precise and 
complex operations. The da Vinci Surgical System provides surgeons with 1) intuitive 
translation of the instrument handle to the tip movement, thus eliminating the mirror-image 
effect, 2) visualization with high quality 3-dimensional images and stable camera platform, 
3) scaling, 4) tremor filtering, 5) coaxial alignment of eyes, hand, and tooltip images, 6) 
EndoWrist with a 360-degree range of motion, 7) comfortable, ergonomically ideal operating 
position. 
 
 
Fig. 1. Da Vinci Surgical System 
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Fig. 2. Robotic platform docked off patient’s right shoulder in 10 degree reverse 
Trendelenburg position, and 10 degree rotation to left. 
It has been demonstrated that minimally invasive surgery is associated with less blood loss , 
shorter hospital stay, less post operative pain , improved cosmesis, and faster recovery 
compared to traditional approaches (32), (33). 10 cases were reported with an operative time 
of 207 minutes, blood loss of 355 cc and nodal yield of 27 (34). It was observed that the 
operative time in robotic radical hysterectomy was 241 minutes and blood loss of 71 cc, and 
no conversion to laparotomy reported (35). 
3. Laparoscopic assesment of disease extent and potential for resectability 
Staging laparoscopy (S-LPS) has been shown to predict optimal cytoreduction in primary 
and recurrent ovarian cancer (36), (37), (38), (39). It has been shown that an objective 
evaluation of the complete debulking is available for primary advanced cases utilizing a 
laparoscopic predictive index score (40- 41). In addition, the inclusion of S-LPS can reduce 
the risk of explorative laparotomies to about 10%, with respect to 20% and 30% obtained 
with the classical criteria of evaluation of response. S-LPS could increase optimal 
cytoreduction in 20% of patients with stable disease. The explanation to this, could be the 
presence of radiological artifacts due to the effects of chemotherapy, such as adherences or 
fibrosis secondary to tumor shrinkage, which would probably alter the diagnostic 
performances of conventional images. The laparoscopic predictive score of surgical outcome 
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has been shown to be reliable in selected group of patients (41-42). The laparoscopic 
parameters meeting the inclusion criteria have been mesenteral retraction, bowel and 
stomach infiltration, and superficial liver metastases. Excluding bowel infiltration, these 
results confirmed others (43-44). It is clear that, S-LPS has an important role in the prediction 
of optimal cytoreduction in advanced ovarian cancer patients at primary diagnosis. 
4. Laparoscopic re-assesment and 2nd look surgery 
Second-look surgical reassessments in patients with advanced ovarian cancer have been 
performed to identify patients who had a complete pathologic response to chemotherapy, as 
demonstrated by numerous biopsies that were negative for persistent cancer. . The surgical 
method involved a laparotomy with extensive exploration of the abdomen, including 
multiple peritoneal washings, multiple biopsies, and, more than often, additional 
retroperitoneal lymph node sampling (45). With the current chemotherapy regimens, 75 - 
80% of patients with optimally cytoreduced disease have a complete clinical response to 
primary chemotherapy, but only 50% of these patients are found to have a negative second 
look (46),(47). About one-half of all patients, who achieve a negative second look develop 
recurrent disease. It has been shown that, there is no survival benefit to the second-look 
procedure (48-51). Laparoscopy had been used to perform second-look evaluations in 
patients with ovarian cancer. Initial studies of second look by laparoscopy reported 
inadequate visualization; a high false-negative rate of between 11 and 55%; a high rate of 
complications, primarily bowel injuries, of 2 to 9%; and a higher recurrence rate following 
negative second-look laparoscopy (52 –55). More recent studies, however, have shown that 
laparoscopic second-look evaluations are equivalent to those performed by laparotomy, but 
are associated with significantly lower blood loss, decreased operating time, short hospital 
stay, and decreased hospital charges (56), (57). The current purpose of laparoscopic second-
look surgery is to identify 3 patients categories: (1) those with microscopic diseases, (2) those 
with resectable disease that can successfully be rendered microscopic, and (3) those with 
gross, unresectable disease. In general, laparoscopy is an efficient and accurate technique for 
surgical reassessment following primary therapy in advanced ovarian cancer patients. 
Despite initial good response rates with primary chemotherapy, the majority of patients 
with advanced ovarian cancer will die of their disease. As approximately 50% of patients 
with a pathologically negative second look will eventually suffer from recurrent disease, as 
these patients all have microscopic disease. Studies have found, that patients with 
microscopic disease at second-look surgical reassessment have a good prognosis and a 5-
year survival rate of 50 to 70% with continued therapy. Furthermore, patients who are 
successfully cytoreduced to microscopic disease at the time of second look have a prognosis 
equivalent to those found to have microscopic disease (58–61). Therefore, this group 
represents a subset of patients who have an overall better prognosis and may potentially be 
curable with effective therapy. Studies have suggested a potential benefit to 
consolidation/salvage therapy in this group of patients (62,63). It appears that microscopic 
disease may be missed by laparoscopy compared with laparotomy, but as all patients in this 
group (both negative-second-look and microscopically positive second-look patients) may 
benefit from consolidation therapy, the small advantage of a more accurate diagnosis of 
microscopic disease does not warrant laparotomy. It has been shown that, the rate of 
positive retroperitoneal nodes as the only evidence of disease at second look was only 3.8% 
(64). Several studies have shown that second-look laparoscopy was considered a promising 
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candidate to replace second-look laparotomy which has been considered as standard 
treatment (65-67). In most initial studies which were conducted involving a small number of 
patients, second look laparoscopy did not produce satisfactory results and inappropriate 
operative field was reported to reach up to 12% and resulted in a false negative rate between 
29.1% and 55% (65,68,69). It has been shown that patients in complete remission after 
chemotherapy underwent laparotomy and histological examination right after suspicious 
lesions were detected by second-look laparoscopy. As a result, the positive and negative 
predictive values of laparoscopy were 100% (six of six cases) and 86% (two false-negative 
out of 14 cases), respectively. Thorough observation of intraperitoneal lesions was available 
in 95% of patients in the LT group and only in 41% of patients in the LPS group due to 
intraperitoneal adhesions after previous surgeries. Though this study has some limitations 
in which postoperative survival rates were not compared with the results of the operation, it 
suggested that second look laparoscopy was less reliable than second-look laparotomy (67). 
Russo reported similar results (70). In a retrospective study by Husain on 150 cases of 
second look laparoscopy (71), the procedure was reported to be safe and accurate as a 
second-look operation. Also, the authors observed that the complication rates were 
reportedly low when laparoscopy was performed on patients who had received a primary 
debulking operation, and the recurrence rates of laparoscopic 
second-look in patients with histologically negative findings and a negative predictive value 
were also reported to be equivalent to those in patients who 
underwent laparotomic second-look (71). Second-look laparoscopy is thought to have 
disadvantages including limited access to lesions due to adhesions formed after previous 
surgeries, inappropriate operative fields and difficulty in manual examination of lesions. 
However, it has several advantages to offset these disadvantages. These are: 
1. When using second-look laparoscopy not for removal of lesions but for diagnosis, the 
preoperative imaging procedure enables the extent and duration of operation to be 
predicted equivalently to those in non-invasive surgery, 
2. Enlarged laparoscopic images enable the detection of minute lesions, 
3. A certain degree of adhesion due to previous surgeries does not affect the performance 
of experienced laparoscopists (76), (77). 
Currently, advanced laparoscopic procedures are increasingly being 
utilized as an alternative to laparotomy in gynecological surgery.(72-74). A meta-analysis of 
27 prospective randomized trials has proven the benefits of laparoscopic compared with 
abdominal gynecologic surgery: decreased pain, decreased surgical-site infections 
(decreased relative risk 80%), decreased hospital stay (2 days less), quicker return to activity 
(2 weeks sooner), and fewer postoperative adhesions (decreased 60%).(75) 
5. Minimally invasive thoracic surgery for patients with advanced ovariian 
cancer 
In advanced and recurrent ovarian cancer, the presence of macroscopic intrathoracic disease 
may alter patient management, particularly if less than 1–2 cm intrathoracic tumor deposits. 
That would leave the patient with suboptimal residual disease at the conclusion of 
maximum intra-abdominal cytoreduction. It has been reported that rate of optimal primary 
debulking ranges from 27% to 51% (78), (79) and (80). The benefits of debulking in patients 
with malignant pleural effusions compared with other stage IV disease criteria have been 
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evaluated. In a study of 84 patients with stage IV disease, including 38% of those patients 
with malignant pleural effusions, in a study it was reported a median survival of 38.4 
months in optimally debulked patients (≤ 1 cm) and 10.3 months for patients with 
suboptimal residual disease (P = 0.0004) (79). On univariate analysis, there was no difference 
in median survival comparing patients with pleural effusion and other stage IV criteria. 
Although several retrospective reviews have demonstrated a survival benefit to optimal 
intra-abdominal debulking in patients with malignant pleural effusions, these patients still 
have decreased survival when compared with patients who have disease confined to the 
abdomen. Evaluating optimally cytoreduced stage IIIC and stage IV patients, it has been 
reported (82) reported a median survival of 58 months for patients who had stage IIIC 
disease and 30 months for patients with stage IV disease (p = 0.016). In patients with 
symptomatic malignant pleural effusions, video-assisted thoracic surgery (VATS) provides 
therapeutic benefits, as thoracoscopic pleurodesis is an effective technique for performing 
pleurodesis, particularly when using talc as the sclerosant. It was observed that the use of 
more extensive ablative techniques and radical upper abdominal procedures is required to 
achieve optimal cytoreduction (83). The involvement of the diaphragm in patients with 
ovarian cancer is the limiting factor preventing optimal cytoreduction (84). Diaphragmatic 
superficial tumor studding can be ablated or resected using diaphragmatic peritonectomy. 
Several authors have described the use of extensive diaphragmatic resections for full 
thickness or deeply invasive diaphragmatic disease (85, (86). VATS may be helpful in 
evaluating the extent of superficial and full thickness diaphragmatic disease and can then be 
used to plan appropriate intra-abdominal surgical approaches. In patients with isolated 
pleural-based disease, VATS can also facilitate intrathoracic cytoreduction. The outcomes of 
30 patients who underwent thoracoscopy either by a transdiaphragmatic approach at 
laparotomy was observed, or through the chest wall prior to a planned abdominal 
procedure (81). In this series, 33% (10/30) underwent pleural implant ablation and/or 
tumor excision, which influenced the final cytoreductive outcome (87). VATS should be 
considered for incorporation into the standard management algorithm for patients with 
advanced ovarian cancer and pleural effusion. The rate of pleural involvement is 
underestimated in patients with advanced ovarian cancer. Preoperative computed 
tomography (CT) identified only one third of patients who had macroscopic pleural nodules 
by video-assisted thoracoscopy (VAT) (88). Occult pleural involvement may be present in up 
to 84% of patients with abdominal diaphragmatic involvement. (89). Without routine pleural 
exploration, failure to remove thoracic lesions occurs in up to one third of patients (89). It has 
been reported that VAT is feasible and safe in patients with advanced ovarian cancer (87).  
Pleural metastases are common in patients with ovarian malignancies and pleural effusions. 
Previously reported rates range from 42% to 65%, Video-assisted thoracoscopy is better than 
CT for evaluating pleural involvement. In a retrospective study of 12 patients with large 
pleural effusions, chest CT detected pleural lesions in only 2 of 6 patients who had pleural 
disease by VAT.(87).  
Routine examination of the pleural cavity may improve staging accuracy, even in patients 
with limited abdominal involvement. In another study, the result of VAT influenced 
treatment decisions in 33% of patients, (87).  
Pleural involvement has been shown to influence patient outcomes (90). In a retrospective 
study, median survival after optimal cytoreductive surgery was 58 months in patients with 
stage IIIC disease and 30 months in those with stage IV disease (P = 0.016). This survival 
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difference may be attributed to residual intrathoracic disease responsible for decreased 
efficacy of complete abdominal cytoreduction or to tumor aggressiveness in patients with 
stage IV disease. Extensive thoracic cytoreductive surgery has been suggested in 
combination with abdominal surgery. It has been reported (91) that performing VAT may 
translate into therapeutic benefits in 30% of cases. Other studies found better survival in 
patients who underwent complete cytoreductive surgery (91), (92).  
Ovarian cancer usually spreads along different routes: lymphatic, haematogenous and 
transcaelomic. One of its features is the possible peritoneal and pleural dissemination. 
Mediastinal lymph node metastasis predicts poor prognosis (93). CPLN colonization is 
frequently associated with intrathoracic disease, which presents as right-sided pleural 
effusion. This is explained by the anatomic arrangement of abdominal lymphatic drainage, 
which follows a clockwise route, involving first the thoracic lymphatic stations on the right 
side. Metastatic calcification of supradiaphragmatic nodes from ovarian primary, is an 
interesting phenomenon, and is reported with an incidence up to 35%. Calcified 
intrathoracic nodes in patients with previous ovarian serous adenocarcinoma cannot be 
ruled out as granulomatous disease, but metastatic deposits must be excluded. Progressive 
growth of the involved station will point out to the latter. FDG-PET scan proves to be 
unreliable because granulomatous lymphadenitis which show an increased FDG-uptake. 
Surgery for patients with ovarian cancer is carried to achieve histologic diagnosis, disease 
staging, and prolonged survival, and Videothoracoscopy is a reliable procedure for that. The 
minimally invasive approach enables thorough exploration of the entire pleural cavity, easy 
resection of any small nodes sited within the pericardial fat, and removal of bilateral CPLN 
growths. Resection of isolated node metastases could improve outlook for slow growing 
tumors. It has been shown that ovarian tumor growth rate seems a sound parameter (93).  
6. Laparooscopic assisted diaphragmatic and hepatic surgery in patients 
with advanced ovarian cancer 
Advanced ovarian cancer spreads along the peritoneal surfaces to the abdomen, and often it 
involves the upper abdomen by direct extension or by peritoneal implantation. Metastases 
to the diaphragm, especially to the right hemi-diaphragm, are common in patients with 
advanced ovarian cancer, and up 40% of patients with advanced ovarian cancer present 
with bulky metastatic diaphragmatic disease. The current standard treatment for primary 
ovarian cancer consists of maximum cytoreductive effort to reduce residual tumor (RT), 
followed by platinum-based chemotherapy (94), (95). It has been observed that 
cytoreduction has a more significant influence on survival than the extent of a metastatic 
disease observed before surgery(96); this target has value not only in the primary 
cytoreduction (94), but also in interval debulking surgery after neoadjuvant chemotherapy 
(97), and in secondary cytoreduction in platinum-sensitive recurrent ovarian cancer patients 
(98). It is accepted that upper-abdominal spread of disease represents a major limit to 
achieve an optimal residual disease after primary cytoreduction (99). Extensive upper 
abdominal debulking surgery increases the rate of optimal cytoreduction and it is related 
with improved survival rates in advanced ovarian cancer undergoing primary 
cytoreduction and interval debulking surgery (100). Thus, hepatic resection(99), 
splenectomy [102] and [103], video-assisted thoracic surgery [104], and diaphragmatic 
resection [105], [106], [107], [108], [109], [110] and [111] have been advocated as components 
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of radical primary cytoreduction . The aim of surgery in advanced or recurrent ovarian 
cancer patients should be the removal of any macroscopic intra-abdominal disease. It has 
been shown (94) that each decrease of 10% in residual tumor volume is followed by an 
increase of 5.5% in median survival in advanced ovarian cancer patients. The diaphragmatic 
implants can be resected with various surgical techniques, as ABC, peritonectomy or muscle 
resection. As previously suggested [112], [115]. The complete understanding of the upper 
abdominal anatomy and of the liver mobilization maneuvers are essential to allow 
exploration and radical debulking of the diaphragm, and minimizing the risk of major 
vessels injuries (retro-hepatic caval vein, supra-hepatic veins, diaphragmatic vessels) with 
severe haemorrhage. It has been reported that the most frequent complication is pleural 
effusion (42.5%) (114). It was observed, using multivariate analysis, that pleural effusion 
was statistically well predicted only by hepatic mobilization. Data from 2 reports [107], [113] 
showed that pulmonary complications represented the main morbidity of diaphragmatic 
surgery and suggest that the respiratory status of patients with diaphragmatic perforation 
should be carefully observed postoperatively. The insertion of intra-operative chest tube 
should be considered in patients undergoing complete liver mobilization and large 
diaphragmatic peritoneal or full thickness resection. Moreover, a strict early post-operative 
pulmonary follow-up should reduce the rate of chest complications. In metastatic ovarian 
carcinoma, involving the dome of the right hepatic lobe are encountered, and this requires 
radical full-thickness resection of a portion of the muscular diaphragm. Secondary 
cytoreductive surgery is an acceptable treatment paradigm for patients with platinum 
sensitive [progression-free survival (PFI) at least 6 to 12 months], recurrent ovarian cancer, 
who have a good performance status and can subsequently undergo platinum-based 
salvage chemotherapy [116]. Optimally resected patients have an 18 to 25 months survival 
advantage over those left with bulky disease ([117), (118] and completely resected patients 
have overall median survival in excess of 44 months [119], (120). Hepatic resection of 
recurrent ovarian and fallopian tube cancers has been reported by Yoon et al [119} with a 
series of 24 patients collected over 14-years in a single institution. Most (88%) were 
completely resected and the median survival was 62 months (range, 6 to 94). Fifty percent of 
patients also required diaphragm resection in this series [121]. Robotic-assisted major and 
minor hepatic resections have been described for management of benign and malignant 
liver lesions. It has been reported that conversion to laparotomy was low (5.7%), mean 
estimated blood loss 262 ml, mortality 0%, and morbidity 21.4% [122]. The majority of the 
malignant lesions were hepatobiliary primary or metastatic cancers, and only two cases 
required a partial diaphragm resection. 
Port placement for this procedure requires careful preoperative planning based on the 
anatomic location of the hepatic lesion. The camera should be triangulated 11 cm from the 
operative table. The laparoscopic Habib 4X® can be useful for cauterization of surrounding 
parenchyma, especially for lesions deeper in the liver. Diaphragm resection performed by 
laparotomy results in a pneumothorax that can be evacuated using a red rubber tube and 
suction from a syringe applied just prior to tying the running suture, while the lung is 
temporarily hyperinflated. A study [121] reported on management and outcomes from 9 
laparoscopic diaphragm injuries or resections accumulated over a 10-year experience. In all 
cases, a 14 Fr rubber catheter was introduced through a port and placed to water seal while 
the anesthesiologist hyperinflated the lungs, expelling excess CO2 from the chest cavity 
prior to tying the final diaphragm suture. Only one patient had a pneumothorax on post-
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extubation chest X-ray and it resolved spontaneously. Based on their experience and, they 
recommended reserving chest tubes only for patients symptomatic with greater than 30% 
pneumothorax. In general, performance of hepatic and diaphragm resections for recurrent 
ovarian cancer can be associated with considerably extended patient survival when 
followed by platinum-based chemotherapy. This procedure is successfully performed with 
robotic-assisted laparoscopy. The technique involves, general anesthesia, the patient is 
placed in a supine position, and 5 trocars are used. Pneumoperitoneum to 12 mmHg is 
established. A 12-mm trocar for the robotic camera is placed above or below the umbilicus 
by the Hassen method. Three additional 8-mm trocars are placed at the left upper quadrant 
(LUQ) epigastric, and right upper quadrant (RUQ) areas under the laparoscopic guidance, 
respectively. A 12-mm trocar for an assistant was also placed at the LUQ area. Insertion sites 
of trocars are slightly different for each case because of additional procedures. The 4-arm da 
Vinci surgical robot system is brought into position and docked following port placement. 
The operator moved to the console to control the robotic arms. The assistant remained at the 
patient's left side to change robotic instruments and perform clipping, stapling, 
intraoperative ultrasonography, and choledochoscope through the 12-mm LUQ trocar site. 
30° robotic camera was used. After exploration of the abdominal cavity, intraoperative 
ultrasonography is used to examine the remaining liver to search for undetectable lesions 
and obtain adequate surgical resection margins, and hepatic resection is performed.  
A closed suction drain catheter is placed in the subhepatic space. The specimen was placed 
in an endoscopic retrieval bag and removed through a left subcostal mini-laparotomy 
incision extending from the port site. 
Robotic surgery enables the operator to control the robotic system alone and to perform 
more precise and complex operations, and possibility of remote site surgery (123- 124). 
Robotic liver surgery provides access to fine structures of the liver and allows visualization 
of blood vessels and ducts. Three-dimensional vision offers the advantage of improved 
depth-perception and accuracy. Robotic surgery has several limitations: 1) high cost, 2) 
inadequate coverage by medical insurance, 3) lack of tactile sense, that can impair surgeons' 
capacity to make intuitive decisions, 4) lack of training systems, 5) heavy robotic arms and 
equipments, 6) time-consuming set up, and 7) difficulty in converting to open surgery. (125-
126).  
In addition, resected hepatic parenchymal metastasis in patients with primary epithelial 
ovarian carcinoma have favorable outlook with an actuarial 3 year cancer survival of 78% 
after resection. From surgical standpoint, the use of parenchymal –sparing segmental 
resections and decrease in the number of hepatic segments resected have substantial 
influence on decline in blood loss, the use of blood products and, hospital stay (3). 
Moreover, laparoscopic surgery or robotic assisted laparoscopic surgery is ideal for these 
cases. The same oncologic rules would apply, including “non –touch technique, RO radical 
resection and, the achievement of tumor-free surgical margin. Moreover, it was observe that 
overall morbidity, biliary leakage, transfusion rates, and mortality revealed no difference 
between the clamp crushing and other alternative transaction techniques (127), (128). 
7. Minimally invasive Splenectomy in advanced ovarian cancer 
To achieve optimal cytoreductive results in patients with advanced-stage ovarian cancer, 
splenectomy may be required when disease involves the hilum, capsule, or parenchyma of 
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the spleen. In patients with extensive omental involvement extending into the splenic hilum, 
complete removal of the omentum can be safer, with less blood loss, if the spleen is removed 
en bloc with the omentum. 
With the focus on attempting radical cytoreduction to less than 5 mm residual tumor, The 
frequency with which splenectomy is conducted has increased. The major associated 
complications of splenectomy include pleural effusions, pneumonia, thrombocytosis with 
thromboembolism, pancreatic injury, and postoperative sepsis. 
The benefit of ultra- radical surgical cytoreduction in the management of ovarian cancer, 
with the goal of microscopic or minimal residual disease, has been established.  
- The minimally invasive robotic surgical technique for splenectomy, involves placing the 
patient in an incomplete lateral right decubitus position with an anti-Trendelenbourg 
inclination of about 30°. A patient-side cart with robotic arms is positioned on the left 
side of the operating table. A 12 mm Hg pneumoperitoneum is created using an open 
technique and by inserting a Verses needle in the same point and the needle is then 
replaced with a 15 mm trocar. A 30° laparoscope is used in all cases. Three additional 
trocars are used. A lateral approach is used. At the start of the procedure the abdominal 
cavity is examined to detect any accessory spleens, which are identified and removed. 
The first step consists of the dissection of the inferior splenic pole and ligature of the 
lower polar vessels, followed by the dissection and ligature of the short gastric vessels. 
The second step is to approach the splenic pedicle next to the hilum; the ligature of hilar 
vessels is performed as far as possible from the pancreatic tail. 
- This part of the procedure is more precise. The splenorenal ligaments are divided up to 
the splenodiaphragmal attachments. The splenic ligament dissection is performed using 
an ultrasonic device , and the hilar and short gastric vessels are dissected using an 
endovascular stapler. The surgical specimens are removed, laparoscopically, through an 
enlarged median supra or subumbilical incision using an endobag, and the drain is 
removed within 48 hours, to avoid the risk of postoperative infections. 
For optimal laparoscopic splenectomy, first, a gentle dissection to avoid incidental 
hemorrhages or parenchymal rupture due to traction on the spleen and cellular 
dissemination; second, accurate hemostasis and transection of the hilar vessels, and the 
identification and removal of accessory spleens that can cause the failure of the surgical 
procedure. For successful laparoscopic splenectomy, the semi lateral right decubitus 
position associated with a lateral approach to the splenic hilum reduces the risks of 
intraoperative bleeding, which is an important reason for conversion to laparotomy. 
Vaccination in the splenectomized is an important topic. Streptococcus pneumonia is the 
major pathogen in postsplenectomy sepsis, accounting for 50% to 90% of all infections 
(129). It has been observed that 31% of patients who had an overwhelming 
postsplenectomy infection (OPSI) had previously received the appropriate 
pneumococcal vaccine. OPSIs are rare but well-described, life-threatening events that 
can occur after splenectomy (131), (132). The incidence of postoperative infection has 
been estimated to be 3.2%, with a mortality rate of 1.3% (131). When an OPSI occurs, the 
mortality rate increases to 50% or higher (130). Aggressive early management of 
postoperative infection is critical to patient survival (129). The interval from the time of 
a splenectomy to an episode of OPSI varies, from 24 days to 65 years (130). The classic 
manifestation of OPSI is a brief episode of fever with mild nonspecific symptoms that 
rapidly evolve into overwhelming septic shock. It is important to initiate empiric broad-
spectrum antibiotic therapy against Serratia pneumonia, Haemophilus influenzae, and 
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Neisseria meningitides, and await blood culture results. Preoperatively, patients should 
receive the pneumococcal vaccine (Pneumovax), H influenzae vaccine (if available), and 
meningococcal vaccinations approximately 10 to 14 days before surgery to maximize 
immunity (131). Patients who do not receive the vaccine preoperatively should receive 
the appropriate vaccinations in the immediate postoperative period.  
Minor lacerations to the tail of the pancreas that do not involve the major ducts are managed 
with closed suction drainage. The splenic capsule should not be closed as there is no 
evidence that will decrease morbidity (132). 
8. Minimally invasive colorectal surgery in patients with advanced ovarian 
cancer 
Several studies have compared laparoscopic versus open rectal excision for rectal cancer 
(133). There were no difference in morbidity, rate of pelvic sepsis and mortality in both 
groups (134), (135). Histopathologic assessment of the rectal reflects the quality of resection 
in rectal cancer surgery. Both distal and circumferential resection margins are risk factors of 
recurrence after rectal excision. (136), (137). It has been shown that laparoscopic approach 
for rectal cancer is an oncologic safe procedure (138). The surgical technique for rectal 
metastatic involvement , secondary to advanced ovarian cancer is as follows: patients have a 
mechanic bowel preparation the day before the operation and prophylactic antibiotics are 
given at the time of surgery. High ligation of the inferior mesenteric artery and mobilization 
of the splenic flexure are performed. For upper third rectal tumors, a 5-cm mesorectal 
excision with end-to-end colorectal anastomosis is performed, for mid and low rectal 
tumors, TME with pouch supra-anal or anal anastomosis is performed, and 
abdominoperineal excision is performed when the levator muscle is invaded. Mesorectal 
excision includes complete removal of the mesorectum circumferentially with preservation 
of the hypogastric and pelvic plexuses. Extra facial anatomic dissection of the mesorectum is 
performed. The rectum is transected with a linear stapler, or transanally according to the 
level of the tumor. For very low tumors, intersphincteric resection is performed to achieve 
sphincter preservation with clear distal margin. The anastomosis is fashioned using a 
mechanical circular stapler. A colonic pouch is performed when feasible. A loop ileostomy is 
performed when the anastomosis is below 5 cm from the anal verge. Pelvic suction drain is 
inserted. In addition, the distal part of rectal dissection is performed by the perineal 
approach and a manual coloanal anastomosis is done. The goal of this minimally invasive 
procedure is to optimize obtaining distal and circumferential safe margins, and to decrease 
pitfalls due to a difficult laparoscopic low stapling.  
Postoperative analgesia is ensured by intravenous morphine chloridrate (patient-controlled 
administration) at a maximum of 4 mg per hour with a single dose of 1 mg and free interval 
of 10 minutes for 1 to 2 days. Nasogastric tube is removed at the end of the surgical 
procedure, fluids intake on postoperative day 1, oral solid food at postoperative day 2 or 3, 
and bladder catheter removal on postoperative day 3.  
The rectal specimen is examined in the operative room to assess distal resection margin, then 
addressed freshly to the pathologic department pinned on a cork board with moderate 
tension. The surface of the mesorectum is inked before slicing to assess the circumferential 
resection margin. Microscopic assessment included tumor infiltration through the bowel wall 
(pT), presence of positive lymph nodes, and distal and circumferential resection margins. The 
resection margin is considered as negative if >1 mm (R0) and positive if <=1 mm (R1).  
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9. Minimally invasive lower urinary tract surgery in invasive ovarian cancer 
In patients with advanced or recurrent ovarian cancer, who have metastatic lower urinary 
tract involvement, robotic assisted laparoscopic surgery is beneficial. The advantage of 
using the robotic system is that it enables the surgeon to dissect deeply in the narrow pelvic 
floor. Also, it offers a better visualization with the binocular optics generating 3-D 
stereoscopic vision. The utilization of harmonic scalpel allows for control of the pelvic 
sidewall vessels and transaction of the ligaments attachments around the pelvic structures. 
The articulating wristed robotic instrument allows for fine sewing. Robotic surgery for 
advanced ovarian cancer can be achieved by rotating the operating table and relocking the 
robot at the patient’s head. This position will allow dissection and removal of the paraaortic 
lymph nodes, resection of the upper abdominal metastases, and debulking of diaphragm 
and live involvement (139). It has been shown that robotic radical prostatectomy; provide a 
significant advantage in terms of its learning curve especially to surgeons with little or no 
advanced laparoscopic experience (140). It required only 12 cases to achieve proficiency in 
performing robotic assisted radical prostatectomy. Total cystectomy with urinary diversion 
remains the treatment of choice for organ –confined muscle invasive cancer of the urinary 
bladder. Gil et al. (141) reported laparoscopic radical cystectomy, bilateral 
lymphadenectomy, and ileal conduit diversion, with the entire procedure carried out by 
intracorporeal laparoscopic technique. There have been few case reports of laparoscopic 
anterior pelvic exenteration (142), (143). It has been shown that the procedure is feasible and 
if combined with intracorporal urinary diversion. The overall morbidity and hospitalization 
considerably decreased. It is worth noting that, the goal of extensive surgery; anterior pelvic 
exenteration should always be resection of the tumor with tumor free margin. Farghaly 
(144) described the following Technique for urinary bladder invasion in advanced and 
recurrent ovarian cancer: Once the patient is anesthetized, she is placed in the low lithotomy 
position in yellowfin stirrups and her arms tucked at her side. After prepping and draping 
the patient, a standard V-care ® Uterine Manipulator (Conmed Endosurgery, Utica, NY) is 
placed and a foley catheter is inserted into the urinary bladder. A 3-cm incision is made at 
the umbilicus, a Gelport ® is inserted into the incision and trocars are introduced through 
the port with robotic instruments. The patient is then placed in the steep trendelenberg 
position and the da Vinci ® surgical system (Intitutive Surgical, Sunnyvale, CA) is docked 
between her legs. A 10-mm robotic 30 degree scope is used through the 10-mm port and 
robotic monopolar Hook and bipolar Maryland instruments are used through the 
triangulated robotic ports to perform the procedure. The assistant intermittently places an 
endoscopic suction device directly through the port. Ovarian cancer tumor and local 
metastases are debulked to less than 1cm in diameter. The round ligaments are ligated 
bilaterally, and retroperitoneal spaces are developed. The infundibulopelvic ligaments are 
skeletonized and transected. A bladder flap is developed, and the uterine arteries and their 
tributaries are skeletonized and ligated. Pelvic and para-aortic lymph nodes are dissected. 
The anatomical margins for the lymph node dissection were: medially the ureter, laterally 
the body of the psoas muscle and genitofemoral nerve, posteriorly, the obturator nerve, 
inferiorly, the deep circumflex iliac vein, and cephalic of the midportion of the common iliac 
artery. The superior limit of the para-aortic dissection is the inferior mesenteric artery. The 
bladder is dissected with its covering. Peritoneum in the cave of Retzius and ureters are 
clipped and cut. The vagina is cut with harmonic shears and this cut is extended anteriorly 
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into the urethera and the entire specimen is disconnected. The paracolpos is cut with 
Ligasure till the levator ani muscle with endopelvic fascia is seen. The entire specimen; 
uterus, ovarian tumor tissues, fallopian tubes and all lymph nodes removed through the 
vagina by placing it in endocatch bag, and the vagina is packed to prevent carbon dioxide 
gas leak. The urinary resvoir is formed by dissecting the terminal ileum about 12 cm from 
the ileocecal valve and the large colon is dissected 15-20 cm distal to the hepatic flexure. The 
transection site of the large colon is performed before the middle colonic artery. The distal 
portion of the ileum is used for continent mechanism of the resvoir. The isolated bowel tract 
is washed using normal saline solution, ringer lactate and antiseptic proidone-iodine 
solution. The isolated bowel tract is then filled with 200 ml. of normal saline, and 6 
teniamyotomies are performed. The tenia is sectioned across the whole width to the 
subumblical layer with, 6 cm between each teniamyotomy. The teniamyotomies are left 
open in order to increase the resvoir capacity of the pouch. The spatulated ureters are 
sutured together at the medial side of spatulation to create a trapezoidal plane which is 
anastomosed to the resvoir as the distal ileum is used as efferent segment of the pouch. The 
distal ileum is cannulated with 14 Fr catheter. The ileocecal valve is reinforced with 2/0 
prolene suture. The tapered ileum is then brought to the anterior abdominal wall. 
Pelvic drain is introduced through the 10mm port and ports were removed under vision. 
The vagina is closed by intracorporeal suturing with 2-0 vicryl and by taking continuous 
interlocking sutures. The fascia is closed using 0 vicryl suture and the skin is closed with 
running 4-0 monocryl subcuticular stitch. Estimated operative time 4.6 hours, and average 
blood loss 210 ml. The pelvic drain is kept for 24-48 hours depending on the drainage. 
Hospital stay is about 5 days. 
This technique offers benefits such as improved surgeon dexterity, enhanced ergonomics 
and 3-D optics. The utilization of ileal conduit formation for urinary diversion is technically 
feasible with good result. Also, it is safe, cost effective, with acceptable operative, 
pathological and short and long term clinical outcome. It retains the advantage of minimally 
invasive surgery 
10. Minimally invasive Surgery for small bowel involvement in patients with 
ovarian cancer 
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have an important 
role in the management of patients with peritoneal surface and small bowel involvement in 
patients with advanced stage ovarian cancer. The patterns of intraceolomic dissemination, 
combined with loco-regional cancer therapies directed at small microscopic residual disease 
constitute the basis of this therapy. Heat and intraperitoneal chemotherapy given at the time 
of surgery after a cytoreduction of the peritoneal tumors has resulted in a significant 
improvement of quality and a prolongation of life in selected patients. The robot –assisted 
laparoscopic or laparoscopic technique involves greater omentectomy. The greater 
omentum is mobilized off the transverse colon and its hepatic and splenic flexures are 
excised using the Harmonic scalpel (Ethicon Inc, Guaynabo, Puerto Rico). The gastrosplenic 
ligament is transected close to the splenic hilum. Bowel resections are performed with an 
Endo GIA 3.5/60 mm cartridge (US Surgical, Norwalk, Connecticut). The bowel mesentery 
is transected with the Harmonic scalpel (Ethicon Inc, Guaynabo, Puerto Rico). At the end of 
the laparoscopic stage of the procedure, a 5 cm periumbilical midline laparotomy is 
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performed and the specimens are extracted. Two inflow and 2 outflow perfusion catheters 
are placed and the skin at the laparotomy and port sites is closed with a running Nylon 
stitch. Hyperthermic intraperitoneal chemotherapy with cisplatin and adriamycin or 
mitomycin C for 90 minutes at 43°C is administered using Thermasolutions 
(Thermasolutions Inc, Pittsburgh, Pennsylvania) perfusion system. At the completion of the 
heated perfusion, gastrointestinal anastomosis is performed. 
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